Cytokinetics Incorporated
CYTK
NGS
Sector: Healthcare
Industry: Biotechnology
50.81
USD
-0.02
(-0.04%)
Optionable: Yes Market Cap: 4,783 M 90-day average vol: 1,419,116
Previous close: 50.83 Open: 50.85 Bid: 52.5 Ask: 52.5
52 week range
29.10 54.74
Last updated: Wednesday 17th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 32.70 |
Price per Book TTM ($) | 45.24 |
PE Ratio (TTM) | -21.00 |
Book Value per Share ($) | 1.18 |
5 Year PE Range | -16.2 , -3.3 |
Returns
7 Day Return | -3.22% | |
1 Month Return | 31.84% | |
3 Month Return | 31.46% | |
1 Year Return | 63.06% | |
3 Year Return | 263.19% | |
5 Year Return | 308.11% | |
YTD Return | 11.47% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 62.36 |
14 Day SMA ($) | 47.85 |
14 Day EMA ($) | 48.41 |
Money Flow Index | 57.79 |
Average True Range | 2.92 |
50 Day SMA ($) | 43.82 |
200 Day SMA ($) | 39.31 |
ADX | 6.72 |
MACD | 2.51 |
Growth
Free Cash Flow QoQ Growth | -55.59% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 191.67% |
Revenue QoQ Growth | -97.94% |
EPS YoY Growth | 0.00% |
Profitability
Return on Assets TTM (%) | -33.99 |
Profit Margin TTM (%) | -119.9 |
Return on Equity TTM (%) | -342.77 |
Return on Capital TTM (%) | -51.9 |
Interest Coverage Ratio | -5.20 |
Gross Margin TTM (%) | -204.0 |
Chart
News
Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment
Yahoo Finance 3/2/2022
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Yahoo Finance 3/1/2022
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
Yahoo Finance 2/28/2022
Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 2/25/2022
Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
Yahoo Finance 2/24/2022
Cytokinetics GAAP EPS of -$0.36 beats by $0.51, revenue of $55.6M beats by $50.04M; initiates FY22 guidance
Seeking Alpha 2/24/2022
Cytokinetics Reports Fourth Quarter 2021 Financial Results
Yahoo Finance 2/24/2022
Cytokinetics Q4 2021 Earnings Preview
Seeking Alpha 2/23/2022
Cytokinetics phase 3 trial of aficamten for heart disease opens enrollment
Seeking Alpha 2/23/2022
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Yahoo Finance 2/23/2022
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
Yahoo Finance 2/17/2022
Cytokinetics announces 3-year collaboration with American Heart Association Bay Area
Seeking Alpha 2/16/2022
Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease
Yahoo Finance 2/16/2022
Cytokinetics Announces Topline Results From METEORIC-HF
Yahoo Finance 2/15/2022
Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Finance 2/15/2022
Goldman Sachs: Buy These 2 Stocks Before They Jump 70% (or More)
Yahoo Finance 2/11/2022
Cytokinetics to Announce Fourth Quarter Results on February 24, 2022
Yahoo Finance 2/10/2022
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: -1.347
Financials
CYTK Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 M | 31 M | 47 M | 29 M | 106 M | 13 M | 32 M | 27 M | 56 M | 70 M |
| Cost of sales | -591000 | -433000 | -490000 | -589000 | -741000 | -2 M | -1 M | -1 M | 95 M | 158 M |
| Gross operating profit | 8 M | 31 M | 47 M | 29 M | 106 M | 13 M | 32 M | 27 M | -41 M | -90 M |
| Selling Gen & administrative expense | 12 M | 15 M | 17 M | 20 M | 28 M | 36 M | 31 M | 40 M | 53 M | 97 M |
| Research & development expense | 36 M | 49 M | 44 M | 46 M | 60 M | 90 M | 89 M | 86 M | 97 M | 160 M |
| Operating income | -41 M | -34 M | -15 M | -37 M | 19 M | -113 M | -89 M | -99 M | -94 M | -186 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 56000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -184000 | 0 |
| Pre-tax Income (EBT) | -40 M | -34 M | -15 M | -38 M | 16 M | -128 M | -106 M | -122 M | -127 M | -215 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -40 M | -34 M | -15 M | -38 M | 16 M | -128 M | -106 M | -122 M | -127 M | -215 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -40 M | -34 M | -15 M | -38 M | 16 M | -128 M | -106 M | -122 M | -127 M | -215 M |
| Preferred dividends | 1 M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -42 M | -34 M | -15 M | -38 M | 16 M | -128 M | -106 M | -122 M | -127 M | -215 M |
| Depreciation | 591000 | 433000 | 490000 | 589000 | 741000 | 2 M | 1 M | 1 M | 2 M | 2 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -40 M | -33 M | -14 M | -37 M | 20 M | -109 M | -83 M | -93 M | -87 M | -184 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -2.28 | -1.24 | -0.41 | -0.97 | 0.41 | -2.59 | -1.95 | -2.11 | -1.97 | -2.8 |
| Diluted EPS total | -2.28 | -1.24 | -0.41 | -0.97 | 0.39 | -2.59 | -1.95 | -2.11 | -1.97 | -2.8 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!